Variable | GLP-1RA (n = 9684) | SGLT-2i (n = 12,097) | P value | Standardized mean difference |
---|---|---|---|---|
Sex (female %) | 38.1 | 37.0 | 0.152 | 0.022 |
Age (years) | 60.23 (11.00) | 60.82 (10.92) | 0.001 | 0.054 |
Diabetes duration (years) | 7.42 (5.67) | 7.67 (5.79) | 0.012 | 0.044 |
HbA1c (mmol/mol) | 67.55 (14.75) | 67.20 (14.49) | 0.175 | 0.024 |
BMI (kg/m2) | 33.40 (6.04) | 32.41 (5.90) | < 0.001 | 0.166 |
Systolic blood pressure (mmHg) | 135.17 (14.70) | 135.22 (15.07) | 0.856 | 0.003 |
Diastolic blood pressure (mmHg) | 80.46 (9.63) | 80.21 (9.77) | 0.122 | 0.026 |
LDL cholesterol (mmol/L) | 2.56 (0.95) | 2.55 (0.95) | 0.461 | 0.014 |
HDL cholesterol (mmol/L) | 1.13 (0.31) | 1.14 (0.32) | 0.009 | 0.051 |
Triglycerides (mmol/L) | 2.32 (1.58) | 2.29 (1.66) | 0.217 | 0.024 |
eGFR (ml/min/1.73 m2) | 91.32 (24.58) | 92.05 (24.07) | 0.087 | 0.030 |
Microalbuminuria (%) | 20.7 | 20.6 | 0.869 | 0.003 |
Macroalbuminuria (%) | 4.5 | 4.1 | 0.250 | 0.023 |
Smoker (%) | 15.1 | 15.5 | 0.551 | 0.011 |
History of MACE (%) | 15.8 | 17.0 | 0.043 | 0.032 |
Heart failure (%) | 3.5 | 3.8 | 0.353 | 0.014 |
Metformin treatment (%) | 87.3 | 86.6 | 0.175 | 0.021 |
Sulfonylurea treatment (%) | 29.3 | 29.0 | 0.610 | 0.008 |
Alpha-glucosidase inhibitor treatment(%) | 0.4 | 0.4 | 0.412 | 0.012 |
Meglitinide treatment (%) | 5.2 | 5.1 | 0.859 | 0.003 |
Thiazolidinedione treatment (%) | 1.6 | 1.7 | 0.967 | 0.001 |
Antihypertensive medication (%) | 73.9 | 73.9 | 0.986 | 0.001 |
RAS blocker (%) | 65.7 | 65.7 | 0.979 | < 0.001 |
Lipid-lowering medication (%) | 65.0 | 65.3 | 0.705 | 0.006 |